41.22 USD
-0.04 (-0.1%)
ChartMill assigns a Buy % Consensus number of 83% to VERA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 63.71. This target is 54.56% above the current price.
VERA was analyzed by 20 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about VERA.
In the previous month the buy percentage consensus was at a similar level.
VERA was analyzed by 20 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-07 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-10-16 | B of A Securities | Initiate | Buy |
| 2025-08-07 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-08-04 | Wolfe Research | Downgrade | Outperform -> Peer Perform |
| 2025-06-02 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2025-06-02 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-05-07 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-05-07 | Wedbush | Maintains | Neutral -> Neutral |
| 2025-03-04 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-02-27 | Guggenheim | Maintains | Buy -> Buy |
| 2025-02-04 | Wolfe Research | Initiate | Outperform |
| 2024-11-21 | Wells Fargo | Initiate | Overweight |
| 2024-11-08 | Wedbush | Maintains | Neutral -> Neutral |
| 2024-11-05 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-10-28 | Guggenheim | Maintains | Buy -> Buy |
| 2024-10-16 | ScotiaBank | Initiate | Sector Outperform |
| 2024-10-03 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-10-01 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-09-23 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-09-16 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-09-09 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-09-06 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-09-03 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-08-13 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-05-31 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-05-10 | Raymond James | Maintains | Strong Buy -> Strong Buy |
| 2024-04-05 | Guggenheim | Reiterate | Buy -> Buy |
| 2024-03-27 | Guggenheim | Maintains | Buy -> Buy |
| 2024-03-21 | Wedbush | Maintains | Neutral -> Neutral |
VERA THERAPEUTICS INC / VERA FAQ
What is the price target for VERA stock?
20 analysts have analysed VERA and the average price target is 63.71 USD. This implies a price increase of 54.56% is expected in the next year compared to the current price of 41.22.
What is the consensus rating for VERA stock?
The consensus rating for VERA THERAPEUTICS INC (VERA) is 83 / 100 . This indicates that analysts generally have a positive outlook on the stock.